From the Seven Deadly Sins to a Risk Management Plan

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.23, Iss.5-6, 2009-10, pp. : 275-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Off-label use of antimalarial prompts risk management plan

Reactions Weekly, Vol. 1, Iss. 1310, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Currently, the US FDA is not requiring changes to the prescribing information of Tysabri [natalizumab] or to the risk management plan

Reactions Weekly, Vol. 1, Iss. 1271, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Snake Venom: From Deadly Toxins to Life-saving Therapeutics

Current Medicinal Chemistry, Vol. 24, Iss. 17, 2017-07 ,pp. : 1874-1891

Bentham Science Publishers

Access to resources Recommend Favorite

Risk management plans – one year on from the EMEA guidelines

Reactions Weekly, Vol. 1, Iss. 1130, 2006-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Risk Management from an Asian/Pacific Rim Regulatory Perspective

By McEwen J.

Drug Safety, Vol. 27, Iss. 8, 2004-01 ,pp. : 491-497

Adis International

Access to resources Recommend Favorite